Liponucleotide-based therapy for ards

Abstract

Compositions and method are therefore disclosed for treating ARDS. In particular, disclosed a composition that contains one, two, or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG) in a pharmaceutically acceptable carrier for use in treating ARDS.

What is claimed is: 
     
         1 . A method for preventing an acute respiratory distress syndrome (ARDS) in a subject, comprising administering to a subject at risk for ARDS an effective amount of a composition comprising one or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, CDP-diacylglycerol (CDP-DAG), and combinations thereof, wherein CDP-conjugated precursors are the only active ingredient and/or wherein the composition does not comprise a nucleotide. 
     
     
         2 . The method of  claim 1 , wherein the composition comprises two or more cytidine diphosphate (CDP)-conjugated precursors selected from the group consisting of CDP-choline, CDP-ethanolamine, and CDP-diacylglycerol (CDP-DAG), in a pharmaceutically acceptable carrier. 
     
     
         3 . The method of  claim 1 , wherein the composition comprises CDP-choline. 
     
     
         4 . The method of  claim 1 , wherein the composition comprises CDP-choline, CDP-DAG, and CDP-ethanolamine. 
     
     
         5 . The method of  claim 1 , wherein the composition consists essentially of CDP-choline and CDP-DAG in a pharmaceutically acceptable carrier. 
     
     
         6 . The method of  claim 1 , wherein the composition is administered intravenously, orally, or by inhalation. 
     
     
         7 . The method of  claim 1 , wherein the composition is in a powder or tablet form. 
     
     
         8 . The method of  claim 1 , wherein the subject has a direct lung insult capable of causing ARDS. 
     
     
         9 . The method of  claim 8 , wherein the direct lung insult is selected from the group consisting of a viral, bacterial, or fungal infection; toxic gas inhalation; a lung cancer; chemotherapy; acid aspiration; and chest trauma. 
     
     
         10 . The method of  claim 9 , wherein the infection comprises influenza. 
     
     
         11 . The method of  claim 1 , further comprising treating the subject with surfactant therapy. 
     
     
         12 . The method of  claim 1 , wherein the composition is administered to the subject prior to infection with one or more influenza virus strains. 
     
     
         13 . The method of  claim 1 , wherein the composition is administered after the subject has been infected with one or more influenza virus strains but before said subject has developed ARDS.